We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-6.73%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.47B
AUM Growth
-$295M
Cap. Flow
-$1.59B
Cap. Flow %
-35.66%
Top 10 Hldgs %
41.85%
Holding
141
New
13
Increased
10
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$48.9M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$45.3M
3
LUNG icon
Pulmonx
LUNG
+$34.3M
4
AHCO icon
AdaptHealth
AHCO
+$25.6M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$23.7M

Top Sells

Rank Stock Value
1
APR
Apria, Inc. Common Stock
APR
+$54M
2
GKOS icon
Glaukos
GKOS
+$41.9M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$40.1M
4
CNC icon
Centene
CNC
+$36.9M
5
PCRX icon
Pacira BioSciences
PCRX
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 54.44%
2 Financials 1.5%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REVH
51
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
$9.81M 0.22%
1,000,000
– –
TLSI icon
52
TriSalus Life Sciences
TLSI
$265M
$9.8M 0.22%
999,999
– –
INZY
53
DELISTED
Inozyme Pharma
INZY
$9.59M 0.21%
2,344,786
– –
ANTX icon
54
AN2 Therapeutics
ANTX
$178M
$8.8M 0.2%
+584,136
New +$8.86M
NYXH
55
Nyxoah
NYXH
$140M
$8.71M 0.19%
455,262
– –
TMPM
56
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$7.39M 0.17%
750,000
– –
INSM icon
57
Insmed
INSM
$22.7B
$7.16M 0.16%
+304,572
New +$7.08M
PKBO
58
DELISTED
Peak Bio, Inc. Common Stock
PKBO
$7.13M 0.16%
725,000
– –
TERN
59
DELISTED
Terns Pharmaceuticals
TERN
$6.97M 0.16%
2,345,959
– –
QSI icon
60
Quantum-Si Incorporated
QSI
$171M
$6.55M 0.15%
1,400,000
– –
CALC icon
61
CalciMedica
CALC
$11.1M
$6.5M 0.15%
377,265
– –
ONCR
62
DELISTED
Oncorus, Inc.
ONCR
$5.61M 0.13%
3,148,977
– –
VINC
63
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$5.52M 0.12%
68,966
– –
ORTX
64
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.95M 0.11%
694,942
– –
OHPA
65
DELISTED
Orion Acquisition Corp. Class A common stock
OHPA
$4.88M 0.11%
500,000
– –
HOWL icon
66
Werewolf Therapeutics
HOWL
$22M
$4.22M 0.09%
958,125
– –
CGEM icon
67
Cullinan Oncology
CGEM
$1.07B
$3.93M 0.09%
375,585
-296,105
-44% -$4M
AFIB
68
DELISTED
Acutus Medical Inc
AFIB
$3.68M 0.08%
2,648,386
– –
FHTX icon
69
Foghorn Therapeutics
FHTX
$305M
$3.64M 0.08%
+238,865
New +$3.28M
RYTM icon
70
Rhythm Pharmaceuticals
RYTM
$7.28B
$3.35M 0.07%
291,005
-1,576,462
-84% -$13.8M
DCTH icon
71
Delcath Systems
DCTH
$412M
$3.2M 0.07%
500,000
– –
GKOS icon
72
CALL
Glaukos
GKOS
$8.92B
$2.61M 0.06%
45,200
– –
AMWL icon
73
American Well
AMWL
$185M
$1.65M 0.04%
19,556
-30,000
-61% -$2.53M
ANNX icon
74
Annexon
ANNX
$841M
$1.59M 0.04%
583,913
– –
BCAB icon
75
BioAtla
BCAB
$5.64M
$1.45M 0.03%
5,780
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2022 Portfolio in Review

As of Q1 2022, Deerfield Management held 141 positions worth $4.47B, down 6.2% from $4.77B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management withdrew a net $1.59B in Q1 2022, closing 19 positions and reducing 16 holdings. Its most notable exit was Apria, Inc. Common Stock, an estimated $54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 63% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Gilead Sciences worth $45.5M.

  • Deerfield Management's largest Q1 2022 buy was Gilead Sciences: 765,489 shares worth $45.5M.
  • Deerfield Management added most to Pulmonx in Q1 2022, an estimated $34.3M increase.
  • Deerfield Management's biggest Q1 2022 reduction was Glaukos, cutting an estimated $41.9M.
  • Deerfield Management fully exited Apria, Inc. Common Stock in Q1 2022, selling an estimated $54M.
  • Deerfield Management's ten largest holdings make up 42% of its $4.47B portfolio in Q1 2022.
  • Deerfield Management opened 13 new positions and closed 19 in Q1 2022.
  • Deerfield Management's portfolio value fell 6.2% quarter-over-quarter to $4.47B.

Based on Deerfield Management's 13F filing for Q1 2022, filed 16 May 2022.